Abstract Library

#1356 Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours

Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Papaxoinis G

Authors: Papaxoinis G, McCallum L, Nasralla M, Hubner R, McNamara M,

Keywords: capecitabine, temozolomide, NET,

#1354 Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome

Introduction: Telotristat etiprate (TE) reduces serotonin production. In TELESTAR, a phase 3 study in patients (pts) with carcinoid syndrome (CS) on somatostatin analogues with ≥4 bowel movements (BM) per day, TE significantly reduced BM frequency (freq). Overall (n=135), durable response (DR, ≥30% reduction in BMs/day for ≥50% of the study period) was observed in 44% (250 mg tid) and 42% (500 mg tid), vs 20% on placebo (PBO); p≤0.02 for each TE vs. PBO. A subset with similar demographics to the overall trial was interviewed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Pavel M, Hörsch D, Anthony L, Ervin C, Kulke M,

Keywords: serotonin, bowel movement, durable response, treatment satisfaction,

#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study

Introduction: CS associated with NETs can have a negative impact on patients’ QoL.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: quality of life,